Home
Tag
InflaRx N.V.
1 article
Company News
InflaRx Shares Jump 22% on AAV Plan
InflaRx shares jumped 22% on May 6, 2026 after announcing Phase 2 planning for oral C5a inhibitor izicopan in ANCA-associated vasculitis. The company will pursue studies in aHUS, IgA nephropathy and C